CHM Cannabis
Home > Boards > US OTC > Delisted >

China BioPharma Corp (fka CHBO)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/20/2017 12:23:10 AM - Followers: 66 - Board type: Free - Posts Today: 0


A/S:  700,000,000

O/S:  53,239,440 as of May 12, 2009

Transfer Agent: Continental Stock Transfer & Trust until 12-31-2010. Current transfer agent unknown.


10-Q May 13, 2009: www.sec.gov/Archives/edgar/data/1190132/000114420409025963/0001144204-09-025963-index.htm



China Biopharma, Inc.
PO Box 6303
Freehold, NJ 07728 USA

Phone: 609-651-8588
Fax: 609-228-4301




Former China office:
China Biopharma, Inc.
173 Yugu Lu, Zhongtian DaSha 16-L
Hangzhou, 310007 China

Now in this office resides Zhongchai Machinery, www.zhongchaimachinery.com . Peter Wang, CEO of China BioPharma Inc., is also President of Zhongchai Machinery.

August 15, 2006 10-Q:
  • During the quarter ended June 30, 2006, the Company entered into a Share Exchange Agreement for the purpose of acquiring 100% of the outstanding capital stock of China BioPharma Limited (CBP) a Cayman Islands Company, which has majority ownership of Tianyuan Bio-Pharmaceuticals Company, Ltd.
May 13, 2009 10-Q: [the latest one]
  • April 7, 2006 China BioPharma Limited has signed an investment agreement with Tianyuan Bio-pharmaceuticals Co., Ltd. to invest into the joint venture partner and the joint venture.
  • The Company entered into a Share Exchange Agreement for the purpose of acquiring 100% of the outstanding capital stock of CBL[China BioPharma Limited], which has rights to invest in Tianyuan Bio-Pharmaceuticals Company, Ltd. and Zhejiang Tianyuan Biotech Co., Ltd. ("ZTBC", now renamed as Zhejiang Kangchen Biotech Co., Ltd. ("ZKBC")). The Company issued a total of 3,000,000 shares of restricted common stock in exchange for 100% of the outstanding capital of CBL.
  • In January 2009, the Company agreed to reduce a receivable amounting to $1,012,700, owed by Zhejiang Tianyuan Bio-pharmaceutical Co. ("Zhejiang Tianyuan"), a 35% minority interest owner in the subsidiary of ZTBC. In exchange, Zhejiang Tianyuan withdrew its 35% equity interest in ZTBC, and ZTBC reduced approximately $1.05 million in the registered capital. As a result, the Company owns 100% control and ownership in ZTBC, and renames it as Zhejiang Kangchen Biotech Co., Ltd. ("ZKBC").




April 10, 2006. Techedge Inc. Signs Definitive Agreement to Acquire China BioPharma Ltd.


  • Techedge Inc. (OTCBB:TEDG) is pleased to announce the acquisition of China BioPharma Limited (CBP), a Cayman Island company, which has majority ownership rights to Tianyuan Bio-pharmaceuticals Co. Ltd., based out of Zhejiang Province, China.
  • Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard... With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees. For more information on their current vaccines please visit www.ty-pharm.com


May 30, 2006. Techedge Inc acquired China BioPharma Ltd.


  • Techedge Inc acquired China BioPharma Ltd, a pharmaceuticals manufacturer. The transaction had been subject to regulatory approval.


July 6, 2006. Techedge Board Has Approved for its New Name As China Biopharma Inc.


  • Techedge, Inc. is a fast growing developer, producer, and distributor of biopharmaceutical products in China. It has wholly owned subsidiary, China Biopharma Limited.
  • Through its investment and ownership of leading Chinese biopharmaceutical companies, the company plans to build the most efficient and most profitable biopharmaceutical company in China by introducing the most advanced technology, best product, and experienced management team.
  • With a fast growing market, newly completed production facility, and several other new vaccines in the pipeline, it is expected to have a steady business growth.


July 18, 2006. Techedge Projects $10,000,000 in sales for 2006.


  • Techedge Inc. has repositioned itself as a developer, producer, and distributor of human vaccine products in China.
  • Techedge has acquired China BioPharma Limited ("CBL") and established its operational joint venture, Zhejiang Tianyuan Biotech Co., Ltd. ("ZTB") in Hangzhou, China.


August 10, 2006. China Biopharma Inc. merged into Techedge. (filing)


  •  On July 14, 2006, Techedge and China Biopharma, Inc, a Delaware corporation and a wholly-owned subsidiary of Techedge executed a Plan and Agreement of Merger whereby the parties agreed to merge CB with and into Techedge, with Techedge being the surviving corporation. By virtue of, and effective upon the consummation of the Merger, the Certificate of Incorporation of the Company was amended to change its name from "Techedge, Inc." to "China Biopharma, Inc." The merger became effective on August 10, 2006.


January 16, 2007. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. is a subsidiary of China BioPharma Limited. (Businessweek report)


  • As of January 16, 2007, Zhejiang  Tianyuan Bio-Pharmaceutical Co., Ltd. is a subsidiary of China BioPharma Limited.
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. develops, produces, and distributes bio-pharmaceutical products in China. It produces viral and bacterial vaccines for influenza infections, haemorrhagic fever with renal syndrome, Japanese encephalitis, and meningococcal meningitis.
  • The company was founded in 1989 and is based in Hangzhou, China.


March 25, 2007. China Biopharma Signed Distribution Agreement with Takeda Pharmaceutical.


  • China Biopharma Inc.'s Chinese subsidiary - Hainan CITIC Biopharmaceutical Development Co., Ltd. - has entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd.  As part of Takeda's goal to expand sales channels in Asia, China Biopharma has begun distributing Serrapeptase tablets, and the agreement with Takeda calls for China Biopharma to distribute additional drugs as hey become available.

  • Based in Osaka, Japan, Takeda is the largest pharmaceutical company in Japan which discovers, develops, manufactures and markets a broad range of superior pharmaceutical products.


March 27, 2008. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products.



September 15, 2008. China Biopharma Inc. Effects 1 for 100 Reverse Stock Split



December 26, 2008. China Biopharma Inc.  Issues Corporate Information Update


  • The Company had significant operational improvement after the start of corporate operational restructuring last year. For the nine months ended September 30, 2008, it has made approximately $5.4 million in sales, more than thirteen times the sales revenue made in the same period of 2007, which was approximately $0.4 million. It also made approximately $90,000 in net profit from the China operation, comparing to a net loss of approximately $0.35 million in the same period of 2007. The Company believes that the current operation will further improve as it finalizes the operational restructuring. 
  • The Company has signed an agreement with Zhejiang Tianyuan Biopharma Co., Ltd. that the Company will increase its stakes from currently 65% to 100% in the joint venture, Zhejiang Tianyuan Biotech Co., Ltd. ("ZTBC"). ZTBC will become a wholly owned subsidiary of the Company, and will change its name to Zhejiang Kangchen Biotech Co., Ltd. It is waiting for the new business license. 
  • The Company has signed an agreement to acquire 90% of Beijing Tiancheng Xinhai Pharmaceutical Co., Ltd. ("BTXP"), a regional pharmaceutical distribution company. The company now has full operating control in BTXP and is waiting for final governmental approval and new business license. 
  • After completion of recent operational restructuring, the company is looking for future merge and acquisitions. The Company is projecting a 25% sales increase in 2009.


November 4, 2009. Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan:

  • Novartis has signed a definitive agreement with the shareholders of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., to acquire an 85% stake for approximately RMB 850 million (USD 125 million in cash). The transaction is subject to certain closing conditions, including receipt of government and regulatory approvals in China.
  • Tianyuan is a privately-owned vaccine company offering a range of marketed vaccine products in China and R&D projects focused on various preventable viral and bacterial diseases. Tianyuan has been delivering dynamic and profitable growth, having more than doubled its net sales to approximately USD 25 million in 2008 compared to 2006.


January 31, 2011. Novartis-Zhejiang Tianyuan acquisition - A $172.92 M

(Australian link, Australian dollars?)


  • Novartis, a world renowned leading multinational pharmaceutical company, was granted approval to acquire an 85% stake of the Chinese private vaccine manufacturer, Zhejiang Tianyuan.
  • This is the first foreign investment in the Chinese vaccine market.


March 16, 2011. Zhejiang Tianyuan Alters the Name into Novartis Tianyuan.


  • The deal marks that the foreign pharmaceutical giant begins deploying the layout in the vaccine market of China's Mainland. Still, Zhejiang Tianyuan has not made the announcement about completion of the deal. Currently, Novartis Tianyuan, the new joint venture between Tianyuan Bio-Pharm and Novartis, is making the development plan for the coming five years. 


March 17, 2011. Novartis Buys 85% Shares of China's Largest Private Vaccine Maker.


  • Switzerland drugs maker Novartis has acquired 85% shares, worth 125 million US Dollars, of Zhejiang Tianyuan Pharmaceutical Company (Tianyuan), China's largest private vaccine producer. Chinese Commerce Ministry has approved the deal, said an unnamed source from Tianyuan.


March 17, 2011. Novartis gets stake approval.


  • According to an agreement signed in 2009, the deal will be settled at approximately 850 million yuan ($125 million). However, [...] the final price would be much higher because of changing market conditions and exchange rates. He did not reveal the exact payment made by Novartis.


March 22, 2011. Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China.


  • Novartis acquires 85 percent stake in Tianyuan, one of the largest privately held vaccines companies in China.
  • Novartis to collaborate with Tianyuan on strengthening its existing product portfolio and expanding its innovation capabilities.
  • Novartis reaffirms its long-standing commitment to improving healthcare for the Chinese people.




  • CHBO owns 100% of China BioPharma Limited (CBL), a Cayman Island company.
  • CBL owns 100% of Zhejiang Kangchen Biotech Co., Ltd. (ZKBC), a product developing subsiadiary. The subsidiary is formely known as Zhejiang Tianyuan Biotech Co.(ZTBC).
  • ZKBC owns 90% of Beijing Tiangcheng Xinhai Pharmaceutical Co. Ltd (BTXP).
  • ZKBC owns 70-90% of Hainan Kangchen Biopharmaceutical Development Co., Ltd. (HKBD). The subsidiary is formerly known as Hainan CITIC Bio-pharmaceutical Development Co (HCBD). This is CHBO's product distribution subsidiary. The percentage of ownership is not clear as filings for acquiring up to 90% of HKBD were not made public; CHBO went pink. The remaining part of HKBD belongs to the Chinese Center for Disease Control.
  • HKBD is China's biggest third-party vaccine distributor licensed to distribute any vaccines and biopharmaceutical products in China. HKBD's distribution network has five regional distribution centers located in Beijing, Shanghai, Guangzhou, Zhengzhou, and Haikou. Each of them have large cool storage facilities. This cold-chain covers 236 major cities in China. During an outbreak, CHBO is able to deliver vaccines within 24 hours to any part of these cities. CHBO has 268 local Chinese Center for Disease Controls as its major customers.
  • According to press releases as well as CHBO's filings, CBL also owned"majority" of Zhejiang Tianyuan Biopharmaceutical Co. that was sold to Novartis on March 22, 2011 for well over $125 million. One of the sources say it was around $173 million.

China Biopharma's Partners:


Takeda, the largest pharmaceutical company in Japan, recognizes the strength of CHBO's distribution network. Takeda is trying to grow their distribution channels in China and had signed a distribution deal with CHBO.

Takeda Products: http://www.takeda.com/products/ethical-drugs/article_896.html

China Biopharma Forms Distribution Agreement with World-Renowned Japanese Pharmaceutical Company Takeda

DASEN® serrapeptase (anti-inflammatory) http://www.chinabiopharma.com.cn/Index_2_Read.asp?PressType=1&ID=61


The company has worked with the Japanese pharmaceutical company, Takeda Pharmaceutical Company, Ltd. ("Takeda"), the largest pharmaceutical company in Japan. With global headquarters located in Osaka, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drugs market, in which it holds the second largest domestic share.

After distributing its products for about ten months on a trial basis, both parties are quite happy with the outcomes and decide to continue this relationship and we will commit more resources and increase our capabilities to carry Takeda's products.



China Biopharma Reaches Agreement to Introduce A New Antiviral Drug: http://www.chinabiopharma.com.cn/Index_2_Read.asp?PressType=1&ID=69

China Biopharma has worked with Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") to introduce a new antiviral medicine into the overseas market including the United States and European countries. This all-natural product has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV by 90% within only 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33.

Disclaimer:*****The moderator and assistant moderators of this forum are not professional financial/investment consultants and reserve the there right to any opinion and share no responsibilty or liable in there or other persons buying or selling stock investment deciscions and ask that persons or investors be advised in seeking there own individual professional financial counseling or due diligence before buying or selling of any stocks.*****








CHM Cannabis
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#4466   Are there any of the shareholders still left siaubas 09/20/17 12:23:10 AM
#4465   CHBO revoked: Renee 07/12/17 09:44:05 AM
#4464   Monthly post. EOM. siaubas 06/14/17 07:01:12 PM
#4463   This $0.01 print is rather strange. siaubas 04/28/17 08:01:51 PM
#4462   CHBO SEC Suspension for delinquent Financials / Filings: Renee 03/22/17 09:35:36 AM
#4461   Monthly Post. EOM. siaubas 03/01/17 07:10:56 PM
#4460   Monthly post. EOM. siaubas 02/07/17 08:26:56 PM
#4459   Monthly post. EOM. siaubas 01/04/17 12:43:40 PM
#4458   Monthly post. EOM. siaubas 11/14/16 02:44:07 PM
#4457   Monthly post. EOM. siaubas 10/12/16 01:29:02 PM
#4456   Monthly post. EOM. siaubas 09/15/16 09:57:59 PM
#4455   Monthly post. EOM. siaubas 08/16/16 03:57:47 PM
#4454   Monthly post. EOM. siaubas 07/21/16 12:51:25 PM
#4453   Monthly post. EOM. siaubas 06/22/16 12:12:46 PM
#4452   Yeah. Here's hoping for the best. Juschilln 05/25/16 01:50:36 PM
#4451   Hopefully. Could easily be a pump-n-dump. Less than siaubas 05/25/16 01:46:42 PM
#4450   We're moving now! Something's up. Juschilln 05/25/16 01:25:47 PM
#4449   Monthly post. EOM. siaubas 05/10/16 01:31:23 PM
#4448   Monthly post. EOM. siaubas 04/10/16 08:49:52 PM
#4447   Monthly post. EOM. siaubas 03/07/16 12:57:29 PM
#4446   Monthly post. EOM. siaubas 02/10/16 01:14:51 PM
#4445   Monthly post. EOM. siaubas 01/12/16 10:39:54 PM
#4444   Monthly post. EOM. siaubas 12/15/15 09:59:39 PM
#4443   Monthly post. EOM. siaubas 11/20/15 07:39:08 PM
#4442   Monthly post. EOM. siaubas 10/17/15 02:09:19 PM
#4441   Monthly post. EOM. siaubas 09/18/15 06:05:20 PM
#4440   Yeah, good point, I guess I'll move on. Juschilln 08/20/15 09:33:52 AM
#4439   I don't quite understand what your expectations are. siaubas 08/18/15 11:10:14 PM
#4438   Ahhh man! That sucks. Can you let Juschilln 08/18/15 08:16:37 AM
#4437   I am not watching this every day, it's siaubas 08/18/15 12:47:19 AM
#4435   Should we get excited today? Juschilln 08/17/15 10:33:44 AM
#4430   One day is not indicative of anything. siaubas 08/03/15 10:41:49 PM
#4429   Boom! Massive volume today. This is starting Juschilln 08/03/15 04:10:27 PM
#4428   Monthly post. EOM. siaubas 07/29/15 02:56:00 PM
#4426   Monthly post. EOM. siaubas 07/01/15 11:16:19 PM
#4424   Monthly post. EOM. siaubas 06/03/15 02:29:23 AM
#4423   If you put this shell up to your PennyGoatTroll 05/22/15 06:52:37 AM
#4422   "Weekly Post" EOM Juschilln 05/15/15 11:47:28 AM
#4421   You can do hourly, if you wish so. siaubas 05/09/15 08:05:51 PM
#4420   LOL! Ok, well can I do "weekly post"? Juschilln 05/09/15 03:29:49 PM
#4419   Why the hell are you posting 'monthly post?' siaubas 05/08/15 11:45:23 PM
#4418   Monthly post. EOM. siaubas 05/08/15 11:42:54 PM
#4417   Monthly post. Juschilln 05/07/15 03:03:15 PM
#4416   Monthly post. Juschilln 04/06/15 01:22:07 PM
#4415   Monthly post. EOM. siaubas 03/23/15 10:33:34 AM
#4414   Monthly post. EOM. siaubas 02/23/15 08:54:21 PM
#4413   Monthly post. EOM. siaubas 01/26/15 12:49:39 PM
#4412   Monthly post. EOM siaubas 12/29/14 01:43:13 PM
#4411   BOOM!? Juschilln 12/09/14 11:04:27 AM
#4410   Monthly post. EOM. siaubas 12/01/14 11:58:33 AM